Veritas遗传公司在中国杭州建立研发中心 开发基于亚洲人群的新型遗传检测技术

  Veritas Genetics公司今日宣布在中国建立R&D中心，用于开发针对亚洲人群的新型遗传产品。
  这个建立的新型研发中心将位于杭州，由Jonathan Zhao出任行政董事，Li Lei任全球临床和监管事务的副总裁，Wang Min人中国研发部副总裁。
  位于波士顿的Veritas公司表示，在中国建立新的研发中心后它们将会履行公司的使命，即通过全球化可获得的遗传筛查产品来进行疾病的预防。
  在中国杭州的新型研发中心将开发新型的遗传产品，这些产品或将对亚洲人群机体常见的独特基因突变进行筛查，比如α地中海贫血症，其是一种遗传性的血液障碍，大约有14%的亚洲人群都携带有致病的罕见基因突变。
  Veritas公司成立于2014年，其最近发起了一项$199的BRCA1和BRCA2的检测技术，该检测名为myBRCA技术，主要针对遗传性的卵巢癌及乳腺癌患者进行检测，上个月myBRCA技术获得CE认证标志。（转化医学网360zhyx.com）
  以上为转化医学网原创翻译整理，转载请注明出处和链接！
转化医学网推荐的新闻阅读：

Veritas Genetics Establishing Asian R&D Center

Veritas Genetics said today it is creating an R&D center in China to develop genetic products targeting the Asian population. 

The new center will be headquartered in Hangzhou and led by Managing Director Jonathan Zhao; Vice President of Global Clinical and Regulatory Affairs Lei Li; and Vice President of China R&D Min Wang. 

Veritas, which is based in Boston, said that with the new center it is carrying out its mission to "make disease prevention through genetic screening products accessible globally." 

The China center will develop products that address "the unique variants which are common in Asian populations," Li said in a statement. Veritas noted as an example alpha thalassemia, an inherited blood disorder for which as much as 14 percent of populations in parts of Asia carry disease variants. 

Veritas was founded in 2014 and recently launched a BRCA1 and BRCA2 test for $199. The test, called myBRCA, for hereditary ovarian and breast cancer received CE marking last month.